Halda's acquisition is a big win for PROTACs

Also: Nuvalent sees success for its second genetically targeted lung cancer drug

November 18, 2025 Check out STAT+

Sponsored By

If you and at least one other friend love STAT and want unlimited access to the latest cancer trial updates, biopharma analysis, and health investigations — our special small group subscription deal may be right for you. Check it out here, and thanks for reading.

Mario Tama/Getty Images STAT+ | Johnson & Johnson acquires Halda Therapeutics for $3 billion, a big win for a buzzy new technology The deal is the first major buyout for a startup built around so-called PROTACs, a field that has attracted big investment but not yet secured approvals.   By Jason Mast NIH funding cuts have affected over 74,000 people enrolled in experiments, a new report says Funding ceased for 383 studies that were testing treatments for conditions including cancer, heart disease, and brain disease. By Associated Press A cervical cancer prevention milestone Today's health news covers an alarming chatbot experiment, a cervical cancer prevention milestone, and more measles vaccine data. By Theresa Gaffney Adobe STAT+ | Nuvalent sees success for its second genetically targeted lung cancer drug ALK+ lung cancer is a dramatic example of how targeting certain enzymes in tumors can produce dramatic results By Matthew Herper

More around STAT

---

In case you missed it Breast cancer and birth control: A huge new study shows how science can be distorted, KFF Health News Kidney cancer cases spiked in a New Hampshire town. Will residents find out why?, The Boston Globe "Better and cheaper": the case for prostate cancer screening among black men, the Guardian

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser